GSK Reports the EMA’s Acceptance of Nucala (Mepolizumab) as an Add-on Treatment for COPD
Shots:
- The EMA has accepted label expansion application of Nucala as an add-on maintenance treatment of COPD pts with an eosinophilic phenotype based on P-III (MATINEE) study
- The MATINEE study assessing Nucala (100mg, Q4W, SC) vs PBO in addition to inhaled triple therapy in COPD pts (n=804) with type 2 inflammation achieved its 1EP, showing significantly reduced mod. or sev. exacerbations over 52-104wks. Data to be highlighted at future conferences
- Nucala (mepolizumab) is a mAb that inhibits IL-5 to reduce blood eosinophil level for producing anti-inflammatory activity in eosinophilic asthma, EGPA & CRSwNP
Ref: GSK | Image: GSK
Related News:- GSK Presents Pooled Analysis from P-III (ANCHOR-1 & 2) Trial of Depemokimab for CRSwNP at AAAAI/WAO Joint Congress 2025
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
